Literature DB >> 25241720

Prevention of misconduct in clinical trials in Japan.

Yoshiki Yui1.   

Abstract

Mesh:

Year:  2014        PMID: 25241720     DOI: 10.1016/S0140-6736(14)61675-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Impact of the Clinical Trials Act 2018 on clinical trial activity in Japan from 2018 to 2020: a retrospective database study using new and conventional Japanese registries.

Authors:  Hiroyuki Taruno; Mari S Oba; Osamu Takizawa; Kayoko Kikuchi; Kazuaki Matsui; Mayumi Shikano
Journal:  BMJ Open       Date:  2022-07-18       Impact factor: 3.006

Review 2.  A perspective on the benefit-risk assessment for new and emerging pharmaceuticals in Japan.

Authors:  Tetsuya Tanimoto
Journal:  Drug Des Devel Ther       Date:  2015-03-31       Impact factor: 4.162

3.  Scientific Misconduct and Social Media: Role of Twitter in the Stimulus Triggered Acquisition of Pluripotency Cells Scandal.

Authors:  Yuya Sugawara; Tetsuya Tanimoto; Shoko Miyagawa; Masayasu Murakami; Atsushi Tsuya; Atsushi Tanaka; Masahiro Kami; Hiroto Narimatsu
Journal:  J Med Internet Res       Date:  2017-02-28       Impact factor: 5.428

4.  Questions Surrounding iPS Cells in Japan.

Authors:  Yoshiki Yui
Journal:  Int J Stem Cells       Date:  2016-05-30       Impact factor: 2.500

5.  Concerns on a new therapy for severe heart failure using cell sheets with skeletal muscle or myocardial cells from iPS cells in Japan.

Authors:  Yoshiki Yui
Journal:  NPJ Regen Med       Date:  2018-03-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.